IBRX Financials
Immunitybio Inc - Financial statements & key metrics
Stock Price
$7.25
Market Cap
$8.03B
EPS
$-0.38
Income Statement Highlights
Most Recent Quarter: 2024-12-31
Revenue
$14.74M
Gross Profit
-
Operating Income
-
Net Income
$-413.64M
EPS (Diluted)
$-0.62
Balance Sheet Highlights
Total Assets
$382.93M
Total Liabilities
$871.06M
Shareholders Equity
-
Cash & Equivalents
$143.43M
Total Debt
-
Cash Flow Highlights
Operating Cash Flow
$-391.24M
CapEx
-
Free Cash Flow
-
Profitability Metrics
Gross Margin
99.3%
Operating Margin
-1.7%
View Complete Financial Statements
Full income statements, balance sheets, and cash flows for multiple periods
Open Full FinancialsFrequently Asked Questions
What is IBRX revenue?
IBRX's most recent quarterly revenue was $14.74M. Annual revenue can be calculated by summing the four most recent quarters.
Is IBRX profitable?
IBRX reported a loss of $413.64M in the most recent quarter.
What is IBRX market cap?
IBRX has a market capitalization of $8.03B, making it a mid-cap stock.
Does IBRX have debt?
View IBRX's balance sheet for debt information.
What is IBRX cash flow?
Cash flow data is available in the full financial statements.